KURA Stock Analysis: Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabo
- Latest close
- $11.04
- 20-day change
- -18.76%
- Trend state
- LEAN BULL
- Classification
- Healthcare · Biotechnology
Market context
Kura Oncology, Inc. moved -18.76% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BULL.
Latest report
The latest cached company filing period (FY2025 · $67.5M revenue · -$278.7M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 3.9/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.